Key facts
- This page summarizes John Dobak's Form 4/A - Amendment filing for DermTech, Inc..
- 2 reported transactions and 0 derivative rows are listed below.
- Accepted by SEC: 06 Apr 2023, 20:08.
John Dobak - 09 Mar 2023 Form 4/A - Amendment Insider Report for DermTech, Inc.
- Reporting relationship
- Chief Executive Officer, Director
- Issuer ticker
- N/A
- Reported as of
- 09 Mar 2023
- Net transaction value
- -$5,082
- SEC form
- 4/A - Amendment
- Accepted by SEC
- 06 Apr 2023, 20:08:53 UTC
- Original report date
- 13 Mar 2023
- Prior SEC filing
- 09 Mar 2023
- Source filing
- View source filing
- Reporting owner signature
- /s/ Mo Tashakor, attorney-in-fact
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
John Dobak filed Form 4/A - Amendment for DermTech, Inc. on 06 Apr 2023.
Change
- Previous filing in this sequence was filed on 09 Mar 2023.
- Current net transaction value: -$5,082.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4/A - Amendment disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
DMTK
transaction
Common Stock
Award
- Transaction value
- $0
- Shares
- +56,407
- Change %
- +8.8%
- Price
- $0.000000
- Shares after
- 700,252
- Date
- 09 Mar 2023
- Ownership
- Direct
- Footnotes
- F1
DMTK
transaction
Common Stock
Sale
- Transaction value
- $5,082
- Shares
- -1,559
- Change %
- -0.22%
- Price
- $3.26
- Shares after
- 698,693
- Date
- 13 Mar 2023
- Ownership
- Direct
- Footnotes
- F2
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 2 footnotes
Footnote F1
Footnote No. 1 in the Form 4 originally filed on March 13, 2023 contained an error regarding the vesting schedule of the restricted stock units awarded to the reporting person. Footnote No. 1 is hereby corrected as follows: The securities awarded are in the form of restricted stock units issued pursuant to the issuer's 2020 Equity Incentive Plan and the terms of a Transition Agreement, dated March 1, 2023, between the reporting person and the issuer. Each restricted stock unit represents a contingent right to receive one share of issuer common stock. Subject to the reporting person's continued service, (i) one-third (1/3) of the restricted stock units shall vest on June 5, 2023 and (ii) the remaining two-thirds (2/3) shall vest in two (2) equal installments of one-third (1/3) on the fifth day of each third month following June 5, 2023 until the final vesting date on December 5, 2023.
Footnote F2
The shares were sold by the reporting person to generate proceeds used to satisfy the tax withholding obligation that arose upon the vesting of certain restricted stock units granted to the reporting person on June 25, 2020.